Press Releases

RSS feed

Alain Schwenck, an Expert on Pharmaceutical Prodcution, becomes Director of Genethon Bioprod

As of 2 April this year, Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon. Mr. Schwenck is a seasoned expert in manufacturing of pharmaceutical products. He began his career at Rhône Poulenc, … [Read more]

Fulvio Mavilio, the internationally acknowledged expert in gene therapy for rare diseases, is appointed as Genethon’s new Scientific Director

Fulvio Mavilio, PhD (aged 58), an internationalacknowledged expert and pioneer in gene therapy for rare diseases for more than twenty years, was appointed as the new Scientific Director of Généthon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (AFM) with donations from France’s annual Telethon) on January 1st, 2012. He succeeds Philippe … [Read more]

Gene therapy : Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C

Evry (France), January 12, 2012 – The results of a Phase I clinical trial of gene therapy for limb-girdle muscular dystrophy type 2C (a rare neuromuscular disease) have just been published in the journal Brain on January 11, 2012. The trial started in December 2006 and has been sponsored by Généthon (the not-for-profit research lab … [Read more]

On the Internet site of the Usine Nouvelle magazine you can discover the Genethon laboratory financed by donations to the Telethon through images from behind the scenes

Both clear and comprehensive, this document will take you to the heart of gene therapy. How can the activities of the Genethon laboratory be explained simply in a few minutes? Usine Nouvelle proposes a guided visit in images of the laboratory created by AFM and financed by Telethon donations. Discover the DNA bank, the imaging … [Read more]

Genethon and Children’s Hospital Boston get FDA approval for a Wiskott Aldrich gene therapy trial

The US Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). After its implementation in Paris and London, this trial based on preclinical research performed at Genethon (Evry, France) which also manufactures the GMP gene therapy product, is now … [Read more]

Genethon and Wake Forest University School of Medicine (North Carolina) announce their collaboration for a preclinical gene therapy trial

Evry (France), March 8th, 2011 – Genethon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM) with donations from France’s annual Telethon) and Wake Forest University School of Medicine (Winston Salem, North Carolina, USA) today announced that they are to collaborate on the preclinical development of a gene therapy for myotubular myopathy. … [Read more]

Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston

A unique multicenter international study of gene therapy for a rare genetic disease (Wiskott-Aldrich syndrome) led in London, Paris and Boston. Genethon, the not-for-profit biotherapy laboratory funded by the French Muscular Dystrophy Association (AFM) thanks to the donations collected during the French Telethon, and Children’s Hospital Boston announce that they have initiated a partnership to conduct a gene therapy … [Read more]

bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

Cambridge, Mass. And Evry, France, December 14, 2010 – bluebird bio (formerly Genetix Pharmaceuticals Inc.), an emerging leader in the development of innovative gene therapies for severe genetic disorders, and Généthon, a leader in the field of gene therapy treatments for rare diseases, today announced a research collaboration focused on process development and scale up efforts for the manufacturing of … [Read more]

Thérapie génique – la découverte d’un mini-gène fonctionnel ouvre une nouvelle voie thérapeutique dans les dysferlinopathies

Read the press release [FR]

Innovative biotherapies and genetic eye diseases

Innovative biotherapies and genetic eye diseases: the Réseau Thérapie Génique Oculaire (Ocular Gene Therapy Network) prepares to launch human trials Tomorrow, around thirty innovative biotherapy and genetic eye disease experts* will gather together at Généthon (Evry) to review, for the first time, the studies carried out so far as part of the Réseau Thérapie Génique … [Read more]